ABSTRACT
Background APOE is a major susceptibility gene for Alzheimer’s disease (AD). Recent studies in Europe and the US have identified rare missense variants (RMVs) in APOE which are significantly associated with AD. However, little is known regarding APOE RMVs in East Asians, including the Japanese, and their association with AD and lipid metabolism.
Objective To identify APOE RMVs in the Japanese population and investigate their association with AD and lipid metabolism, including low-density lipoprotein cholesterol levels.
Subjects APOE RMVs were explored in the NIG (2,589 subjects) and ToMMo (3,307 subjects) cohorts. A case-control study was performed involving 6,471 AD and 20,270 control subjects.
Methods Sanger sequencing or whole-exome sequencing was performed on NIG subjects. We used genotype data from ToMMo. APOE RMV frequencies in the Japanese were compared with various ethnic populations. Associations among APOE RMV genotypes, AD, and lipoproteins were examined.
Results Fourteen RMVs were identified (minor allele frequency 0.02 – 0.73%), 10 of which were specifically found in East Asians. Five RMVs previously reported overseas were not detected in Japanese individuals. Two RMVs (rs140808909 and rs190853081) exhibiting complete linkage disequilibrium were associated with AD protective effects: PBonferroni = 3.63E-02, OR (95% CI) = 0.70 (0.54–0.92). No significant differences in cholesterol levels were observed between RMV carriers and non-carriers.
Conclusions APOE RMVs were identified in the Japanese population, with two showing potential protective effects against AD. Further studies involving larger cohorts are required to confirm our findings and investigate the role of APOE RMVs in AD and lipid metabolism.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by: (1) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 21K07271 (AM); (2) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (B), 21H03537 (AM); (3) AMED, JP21dk0207055 (AM); (4) JSPS Grant-in-Aid for Scientific Research (KAKENHI), 22H04923 (DK); (5) AMED, JP21wm0425019 (MT); (6) Intramural fund from NCNP, Grant Number 6-8 (MT); (7) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 18K06506 (MT); (8) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 21K06417 (MT); (9) JSPS Grant-in-Aid for Transformative Research Areas, 22H04923 (MT); (10) the Research Committee of Prion Disease and Slow Virus Infection, the Ministry of Health, Labour and Welfare Health and Labour Sciences Research Grants, Japan (MT); (11) AMED, JP24wm0425019 (AK) ; (12) AMED, JP21wm0425019 (YS, SM); (13) JSPS Grant-in-Aid for Scientific Research (KAKENHI), 22H04923 (CoBiA) (YS); (14) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C), 22K07550 (YS); (15) MHLW Research on rare and intractable diseases Program Grant Number JPMH23FC1008 (YS); (16) AMED, JP21wm0425019 (MY); (17) MHLW Health, Labour and Welfare Science Research Grants, JPMH23FC1008 (YI); (18) AMED, JP18kk0205009 (SN); (19) AMED, JP21dk0207045 (SN); (20) AMED, JP22dk0207060 (SN); (21) AMED, JP21dk0207045 (KO); (22) AMED, JP22dk0207060 (KO); (23) Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology (24-15) (KO); (24) a grant from the Japanese Ministry of Health, Labour, and Welfare for Research on Dementia (KO); (25) AMED, JP23wm0525019 (MK); (26) AMED, JP23dk0207060 (MK); (27) JSPS Grant-in-Aid for Scientific Research (KAKENHI) (B), 23K27515 (TIwatsubo); and (28) AMED, JP22dk0207060 (TIkeuchi)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Niigata University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study are generally available upon request from the corresponding authors (AM and TIkeuchi). However, the WES data used in this study are not publicly available due to privacy or ethical restrictions.
